Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2020 Oct 29:11:614856.
doi: 10.3389/fimmu.2020.614856. eCollection 2020.

Editorial: Immunogenicity of Proteins Used as Therapeutics

Zuben E Sauna  1 , Susan M Richards  2 , Bernard Maillere  3 , Elizabeth C Jury  4 , Amy S Rosenberg  5
Affiliations
Editorial

Editorial: Immunogenicity of Proteins Used as Therapeutics

Zuben E Sauna et al. Front Immunol. .
No abstract available

Keywords: drug development; drug safety; immune tolerance; immunogenicity; therapeutic proteins.

PubMed Disclaimer

Comment on

  • Editorial on the Research Topic Immunogenicity of Proteins Used as Therapeutics

References

    1. Rosenberg AS, Pariser AR, Diamond B, Yao L, Turka LA, Lacana E, et al. A Role for Plasma Cell Targeting Agents in Immune Tolerance Induction in Autoimmune Disease and Antibody Responses to Therapeutic Proteins. Clin Immunol (2016) 165:55–9. 10.1016/j.clim.2016.02.009 - DOI - PubMed
    1. Wang H, Li G. A Selective Review on Random Survival Forests for High Dimensional Data. Quant Bio-Science (2017) 36:2. 10.22283/qbs.2017.36.2.85 - DOI - PMC - PubMed
    1. Favalli EG, Raimondo MG, Becciolini A, Crotti C, Biggioggero M, Caporali R. The Management of First-Line Biologic Therapy Failures in Rheumatoid Arthritis: Current Practice and Future Perspectives. Autoimmun Rev (2017) 16:12. 10.1016/j.autrev.2017.10.002 - DOI - PubMed
    1. Balsa A, Sanmarti R, Rosas J, Martin V, Cabez A, Gómez A, et al. Drug Immunogenicity in Patients with Inflammatory Arthritis and Secondary Failure to Tumour Necrosis Factor Inhibitor Therapies: the REASON Study. Rheumatology (2018) 57:4. 10.1093/rheumatology/kex474 - DOI - PubMed

Publication types

MeSH terms

LinkOut - more resources